Join to View Full Profile
RemoteBothell, WA 98021
Phone+1 425-570-1942
Dr. Ho is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Linda Ho, based in Bothell, WA, is a pathologist with subspecialties in hematopathology and genito-urinary pathology. She completed her residency at McGaw Medical Center of Northwestern University and pursued fellowships in hematopathology and GU pathology at Case Western Reserve University/University Hospitals Cleveland Medical Center. Currently, she serves as Senior Medical Director at AbbVie, Inc. Her professional experience includes roles focused on hematopathology, hematologic malignancies, and drug development. Dr. Ho has authored several publications in notable journals like Blood and the Journal of Clinical Oncology and has been involved in clinical trials related to Brentuximab Vedotin in classical Hodgkin lymphoma and Diffuse Large B-cell Lymphoma.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical Center Surgical PathologyFellowship, Selective Pathology, 2009 - 2010- Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematopathology, 2008 - 2009
McGaw Medical Center of Northwestern UniversityResidency, Pathology-Anatomic and Clinical, 2003 - 2008
Loyola University Chicago Stritch School of MedicineClass of 2003
Case Western Reserve University BA, Medical Anthropology and Biology, magna cum laude, 1994 - 1998
Certifications & Licensure
CA State Medical License 2012 - 2028
IL State Medical License 2008 - 2009
Clinical Trials
- Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Start of enrollment: 2019 Jan 28
Publications & Presentations
PubMed
- 1 citationsBrentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.Jeremy S Abramson, David J Straus, Nancy L Bartlett, John M Burke, Ryan C Lynch
Blood. 2026-04-09 - 30 citationsBrentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi
Journal of Clinical Oncology. 2025-03-20 - 11 citationsBrentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma.Hun Ju Lee, Rod Ramchandren, Judah Friedman, Jason Melear, Ian W Flinn
Blood. 2025-01-16
Abstracts/Posters
- Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and AboveChristopher A. Yasenchak, MD , Rodolfo Bordoni, MD , Victor Yazbeck, MD , Dipti Patel-Donnelly, MD , Timothy Larson, MD , Trevor Newhook, MS , Linda Ho , Matthew..., American Society of Hematology, Orlando, FL, 11/13/2019
- Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 YearsChristopher A. Yasenchak, MD , Rodolfo Bordoni, MD , Victor Yazbeck, MD , Dipti Patel-Donnelly, MD , Thomas Anderson , Timothy Larson, MD , Trevor Newhook, MS , ..., American Society of Hematology, Orlando, FL, 11/13/2019
- Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin LymphomaJudah Friedman, MD , Hun Ju Lee, MD , Linda Ho , Ian W. Flinn, MD PhD, American Society of Hematology, Orlando, FL, 11/13/2019
Press Mentions
How to Optimize Your Career as an MSL with Dr. Linda Ho – 051September 11th, 2018
Research History
- Senior Medical Director2025 - Present
- Medical Director, Late Stage Clinical Development2021 - 2024
- Associate Medical Director, hematology2018 - 2021
Professional Memberships
- Member
- Member
Other Languages
- Chinese (Mandarin)
Industry Relationships
- Senior Medical Director, AbbVie, Inc.2025 - Present
- Medical Director, Pfizer2024 - 2025
- Medical Director, Seagen, Inc.2018 - 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
